PubRank

M D Boyle

Author PubWeight™ 110.19‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Group A streptococcal growth phase-associated virulence factor regulation by a novel operon (Fas) with homologies to two-component-type regulators requires a small RNA molecule. Mol Microbiol 2001 2.24
2 Cloning, sequence analysis, and expression in Escherichia coli of a streptococcal plasmin receptor. J Bacteriol 1992 2.14
3 Association between expression of immunoglobulin G-binding proteins by group A streptococci and virulence in a mouse skin infection model. Infect Immun 1993 1.92
4 Capturing host plasmin(ogen): a common mechanism for invasive pathogens? Trends Microbiol 1994 1.76
5 Identification of a specific receptor for plasmin on a group A streptococcus. Infect Immun 1987 1.72
6 M-related protein (Mrp) contributes to group A streptococcal resistance to phagocytosis by human granulocytes. Mol Microbiol 1996 1.71
7 Identification of pel, a Streptococcus pyogenes locus that affects both surface and secreted proteins. J Bacteriol 1999 1.39
8 Isolation of a prokaryotic plasmin receptor. Relationship to a plasminogen activator produced by the same micro-organism. J Biol Chem 1991 1.38
9 A secreted streptococcal cysteine protease can cleave a surface-expressed M1 protein and alter the immunoglobulin binding properties. Res Microbiol 1998 1.36
10 Streptococcal Fc receptors. I. Isolation and partial characterization of the receptor from a group C streptococcus. J Immunol 1984 1.33
11 Characterization of the interaction of human plasmin with its specific receptor on a group A streptococcus. Microb Pathog 1988 1.20
12 Isolation and characterization of type IIa and type IIb Fc receptors from a group A streptococcus. Scand J Immunol 1986 1.18
13 Effect of mouse passage on Fc receptor expression by group A streptococci. Scand J Immunol 1984 1.15
14 Streptokinase-producing streptococci grown in human plasma acquire unregulated cell-associated plasmin activity. J Infect Dis 1992 1.15
15 Absence of SpeB production in virulent large capsular forms of group A streptococcal strain 64. Infect Immun 2000 1.13
16 Identification of non-immunoglobulin A-Fc-binding forms and low-molecular-weight secreted forms of the group B streptococcal beta antigen. Infect Immun 1989 1.12
17 Protection of mice from group A streptococcal skin infection by interleukin-12. J Infect Dis 1995 1.12
18 Association of type II immunoglobulin G-binding protein expression and survival of group A streptococci in human blood. Infect Immun 1993 1.10
19 125I protein A: applications to the quantitative determination of fluid phase and cell-bound IgG. J Immunol Methods 1977 1.10
20 Studies on the terminal stages of immune hemolysis. VI. Osmotic blockers of differing Stokes' radii detect complement-induced transmembrane channels of differing size. J Immunol 1979 1.09
21 Functional and serological analysis of type II immunoglobulin G-binding proteins expressed by pathogenic group A streptococci. J Clin Microbiol 1992 1.08
22 Two novel antigens associated with group B streptococci identified by a rapid two-stage radioimmunoassay. J Infect Dis 1988 1.07
23 Measurement of leukocyte chemotaxis in vivo. Methods Enzymol 1988 1.07
24 Isolation and partial characterization of a type II Fc receptor from a group A streptococcus. Mol Cell Biochem 1986 1.07
25 Streptococcal Fc receptors. II. Comparison of the reactivity of a receptor from a group C streptococcus with staphylococcal protein A. J Immunol 1984 1.06
26 Evidence for functional heterogeneity in IgG Fc-binding proteins associated with group A streptococci. J Immunol 1991 1.05
27 Group B streptococcal C protein-associated antigens: association with neonatal sepsis. J Infect Dis 1991 1.04
28 Identification of two type IIa IgG-binding proteins expressed by a single group A streptococcus. J Immunol 1992 1.02
29 Mapping of the human plasmin domain recognized by the unique plasmin receptor of group A streptococci. Infect Immun 1989 1.02
30 Studies on the terminal stages of immune hemolysis. III. Distinction between the insertion of C9 and the formation of a transmembrane channel. J Immunol 1978 1.02
31 Interaction between group A streptococci and the plasmin(ogen) system promotes virulence in a mouse skin infection model. J Infect Dis 1999 0.99
32 Properties of IgG-binding proteins expressed by Streptococcus pyogenes isolates are predictive of invasive potential. J Infect Dis 1996 0.99
33 Isolated DNA repeat region from fcrA76, the Fc-binding protein gene from an M-type 76 strain of group A streptococci, encodes a protein with Fc-binding activity. Mol Microbiol 1990 0.99
34 Detection of receptors for the Fc region of IgG on streptococci. J Immunol Methods 1983 0.99
35 Identification of a unique receptor on a group A streptococcus for the Fc region of human IgG3. J Immunol 1986 0.98
36 A role for fibrinogen in the streptokinase-dependent acquisition of plasmin(ogen) by group A streptococci. J Infect Dis 1995 0.98
37 The potential role for nephritis-associated plasmin receptor in acute poststreptococcal glomerulonephritis. Methods 2000 0.98
38 A group A streptococcal Enn protein potentially resulting from intergenomic recombination exhibits atypical immunoglobulin-binding characteristics. Mol Microbiol 1994 0.97
39 Analysis of the interaction of group A streptococci with fibrinogen, streptokinase and plasminogen. Microb Pathog 1995 0.97
40 Studies on the terminal stages of immune hemolysis. V. Evidence that not all complement-produced transmembrane channels are equal. J Immunol 1979 0.96
41 Studies on the interaction between protein A and immunoglobulin G. II. Composition and activity of complexes formed between protein A and IgG. J Immunol 1978 0.96
42 Nerve growth factor: a chemotactic factor for polymorphonuclear leukocytes in vivo. J Immunol 1985 0.96
43 Differences in cell-bound C8 sites on chicken erythrocytes measured by their reactivity with guinea pig and human C9. J Immunol 1980 0.95
44 Identification of key gene products required for acquisition of plasmin-like enzymatic activity by group A streptococci. J Infect Dis 1997 0.95
45 Mouse skin passage of a Streptococcus pyogenes Tn917 mutant of sagA/pel restores virulence, beta-hemolysis and sagA/pel expression without altering the position or sequence of the transposon. BMC Microbiol 2001 0.95
46 Lysis of tumor cells by antibody and complement. VII. Complement-dependent 86Rb release--a nonlethal event? J Immunol 1976 0.94
47 Nerve growth factor: stimulation of polymorphonuclear leukocyte chemotaxis in vitro. Proc Natl Acad Sci U S A 1983 0.94
48 Analysis of plasmin(ogen) acquisition by clinical isolates of group A streptococci incubated in human plasma. J Infect Dis 1994 0.94
49 Production of Brucella abortus-specific protein A-reactive antibodies (IgG2) in infected and vaccinated cattle. Vet Microbiol 1986 0.94
50 Urokinase: a chemotactic factor for polymorphonuclear leukocytes in vivo. J Immunol 1987 0.93
51 Studies on the terminal stages of antibody-complement-mediated killing of a tumor cell. II. Inhibition of transformation of T to dead cells by 3'5' cAMP. J Immunol 1976 0.92
52 A simple procedure to use whole serum as a source of either IgG- or IgM-specific antibody. J Immunol Methods 1980 0.92
53 Similarities between complement-mediated and streptolysin S-mediated hemolysis. J Biol Chem 2001 0.91
54 Analysis of surface receptor expression on bacteria isolated from patients with endocarditis. J Gen Microbiol 1986 0.90
55 Interaction between components of the human classical complement pathway and immobilized Cibacron Blue F3GA. J Immunol Methods 1979 0.90
56 Streptococcal pyrogenic exotoxin B enhances tissue damage initiated by other Streptococcus pyogenes products. J Infect Dis 2001 0.90
57 The terminal stages of immune hemolysis--a brief review. Mol Immunol 1980 0.89
58 Species specificity of plasminogen activation and acquisition of surface-associated proteolytic activity by group C streptococci grown in plasma. Infect Immun 1999 0.89
59 A rapid technique for measuring leukocyte chemotaxis in vivo. J Immunol Methods 1984 0.89
60 Identification of protein A from Staphylococcus intermedius isolated from canine skin. Am J Vet Res 1988 0.89
61 Studies on the terminal stages of immune hemolysis. IV. Effect of metal salts. J Immunol 1979 0.88
62 Analysis of expression of a cytosolic enzyme on the surface of Streptococcus pyogenes. Biochem Biophys Res Commun 2000 0.88
63 Analysis of immunoglobulin G-binding-protein expression by invasive isolates of Streptococcus pyogenes. Clin Diagn Lab Immunol 1995 0.88
64 Interaction of a group A Streptococcus within human plasma results in assembly of a surface plasminogen activator that contributes to occupancy of surface plasmin-binding structures. Microb Pathog 1998 0.87
65 Lysis of tumor cells by antibody and complement. VI. Enhanced killing of enzyme-pretreated tumor cells. J Immunol 1976 0.87
66 Comparison of type III Fc receptors associated with group C and group G streptococci. Mol Immunol 1986 0.86
67 A pivotal role for interferon-gamma in protection against group A streptococcal skin infection. J Infect Dis 2000 0.86
68 Results of the premature birth national need-gap study. J Perinatol 2007 0.85
69 Studies on the interaction between protein A and immunoglobulin G. I. Effect of protein A on the functional activity of IgG. J Immunol 1978 0.85
70 Distinct profiles of immunoglobulin G-binding-protein expression by invasive serotype M1 isolates of Streptococcus pyogenes. Clin Diagn Lab Immunol 1995 0.85
71 Studies on the terminal stages of antibody-complement-mediated killing of a tumor cell. I. Evidence for the existence of an intermediate, T. J Immunol 1976 0.85
72 Role of staphylokinase in the acquisition of plasmin(ogen)-dependent enzymatic activity by staphylococci. J Infect Dis 1996 0.84
73 Enzyme-labeled type III bacterial Fc receptors. A versatile tracer for immunoassay. J Immunol Methods 1988 0.84
74 Restoration of complement function in vivo by plasma infusion in factor I (C3b inactivator) deficiency. J Pediatr 1984 0.84
75 Distinction between C8-mediated and C8/C9-mediated hemolysis on the basis of independent 86Rb and hemoglobin release. J Immunol 1980 0.84
76 Identification of distinct Fc-receptor molecules on streptococci and staphylococci. J Clin Lab Immunol 1984 0.84
77 Inactivation of single genes within the virulence regulon of an M2 group A streptococcal isolate result in differences in virulence for chicken embryos and for mice. Microb Pathog 1997 0.84
78 Interaction of group A streptococci with human plasmin(ogen) under physiological conditions. Methods 2000 0.83
79 Detection of streptococcal class I M protein in psoriasis by confocal immunofluorescent microscopy. Acta Derm Venereol 1997 0.83
80 The destruction of allogeneic tumour cells by antibody and adherent cells from peritoneal cavities of mice. Cell Immunol 1976 0.83
81 The destruction of tumor cells by alloimmune peritoneal cells: mechanism of action of activated macrophages in vitro. J Reticuloendothel Soc 1975 0.82
82 Group A streptococci bind human plasmin but not other structurally related proteins. Thromb Res 1989 0.82
83 Nerve growth factor: activation of the classical complement pathway by specific substitution for component C1-. Proc Natl Acad Sci U S A 1982 0.81
84 Group A streptococcal isolate 64/14 expresses surface plasmin-binding structures in addition to Plr. Res Microbiol 1998 0.81
85 Comparison of albumin receptors expressed on bovine and human group G streptococci. Infect Immun 1991 0.80
86 Different alleles of the fcrA/mrp gene of Streptococcus pyogenes encode M-related proteins exhibiting an identical immunoglobulin-binding pattern. Med Microbiol Immunol 1996 0.80
87 The destruction of allogeneic tumour cells by peritoneal macrophages from immune mice: purification of lytic effector cells. Cell Immunol 1975 0.80
88 Evidence for a temperature-dependent and temperature-independent pathway in the generation of complement-mediated transmembrane channels. Biochem Biophys Res Commun 1980 0.80
89 Colloidal gold immunolabeling of immunoglobulin-binding sites and beta antigen in group B streptococci. Infect Immun 1990 0.79
90 Antibody-complement killing of neuroblastoma cells. Prog Clin Biol Res 1985 0.79
91 Characterization of a type II'o group A streptococcal immunoglobulin-binding protein. Mol Immunol 1995 0.79
92 Inactivation of the proteolytic activity of mouse nerve growth factor by human C1(activated)-inhibitor. J Immunol 1987 0.79
93 The interaction of pathogens with humans. Methods 2000 0.79
94 Complement-dependent cytotoxic antitumor antibody. I. Immunoglobulin class determined by interaction with protein A or concanavalin A. J Natl Cancer Inst 1978 0.78
95 Effect of concanavalin A on the classical complement pathway. J Immunol 1977 0.78
96 Destruction of allogeneic tumour cells by peritoneal macrophages. Transplantation 1976 0.78
97 Effect of concanavalin A on the hemolytic activity of the components of the classical complement pathway. Mol Immunol 1980 0.78
98 Effect of concanavalin A on the functional activity of hemolytic antibody. Immunol Commun 1977 0.78
99 Subunit structure of high molecular weight mouse nerve growth factor. Biochemistry 1988 0.78
100 Is the membrane attack complex of complement an enzyme? Mol Cell Biochem 1984 0.78
101 Identification of an amino acid signature sequence predictive of protein G-inhibitable IgG3-binding activity in group-A streptococcal IgG-binding proteins. Gene 1996 0.78
102 Purging tumor cells from bone marrow by use of antibody and complement: a critical appraisal. J Natl Cancer Inst 1988 0.78
103 Identification of two functional forms of immunoglobulin G3-binding protein expressed by group A streptococci. Infect Immun 1994 0.77
104 Evidence for independent binding domains within a group A streptococcal type IIo IgG-binding protein. Can J Microbiol 1996 0.77
105 Nerve growth factor accelerates the early cellular events associated with wound healing. Exp Mol Pathol 1985 0.77
106 Relationship between the intracellular cyclic adenosine 3':5'-monophosphate level of tumor cells and their sensitivity to killing by antibody and complement. Cancer Res 1979 0.77
107 Protein B: a versatile bacterial Fc-binding protein selective for human IgA. Biotechniques 1991 0.77
108 Lysis of tumor cells by antibody and complement. III. Lack of correlation between antigen movement and cell lysis. J Immunol 1975 0.77
109 Clot formation by group A streptococci. Infect Immun 1998 0.77
110 Effect of inhibiting DNA, RNA, and protein synthesis of tumor cells on their susceptibility to killing by antibody and complement. Cancer Res 1977 0.77
111 Selective colony blotting to expand bacterial surface receptors: applications to receptors for rat immunoglobulins. Biotechniques 1988 0.76
112 Effect of concanavalin A on the killing of tumor cells by antibody and complement. J Immunol 1977 0.76
113 Evidence for the influence of the initial complement components on the assembly and activity of the membrane attack complex. J Immunol 1980 0.76
114 Mathematical analysis of the reaction of EAC1-8 with C9: identification of parameters defining conditions for molecular titration. J Immunol 1980 0.76
115 Solid-phase radioimmunoassay for the detection of immunoglobulins against bovine Brucella abortus. Vet Immunol Immunopathol 1984 0.75
116 A hygienist talks back. Oral Hyg 1967 0.75
117 Detection of rheumatoid-like factors in serum of chickens immunized with bacterial immunoglobulin binding proteins. J Immunol Methods 1991 0.75
118 Complement-dependent cytotoxic antitumor antibody. II. Quantitative determination of cell-bound immunoglobulin M1. J Natl Cancer Inst 1979 0.75
119 A solid-phase immunoassay for human immunoglobulin E: use of 125I-labeled protein A as the tracer. Anal Biochem 1979 0.75
120 Antigenic distinction between human C9 and guinea pig C9. Clin Immunol Immunopathol 1979 0.75
121 Effect of protease treatment on the sensitivity of tumor cells to antibody-GPC killing. Clin Immunol Immunopathol 1978 0.75
122 Differences in the functional activity of human and guinea pig C1 based on their reactivity with IgG at low temperature. Mol Immunol 1981 0.75
123 Interaction of bovine immunoglobulin gamma 2 (IgG2) with staphylococcal protein A: evidence for IgG2a and IgG2b sub-subclasses in the bovine. Comp Immunol Microbiol Infect Dis 1985 0.75
124 Quantitation of antibody-complement mediated lysis of tumor cells. J Immunol Methods 1977 0.75
125 Regulation of the activation of C1 in serum. Mol Immunol 1987 0.75
126 Nerve growth factor. A structural relationship between its proteolytic and leukocyte-chemotactic active sites. Mol Cell Biochem 1985 0.75
127 Interaction of bacterial Fc receptors with goat immunoglobulins. Mol Immunol 1985 0.75
128 Inhibition by zinc of the binding of C1 to antigen-antibody complexes. Biochem Biophys Res Commun 1981 0.75
129 Restriction in the lytic efficiency of complement of different erythrocyte targets: a re-examination of the activities of horse C8 and C9. Mol Immunol 1986 0.75
130 Immunological applications of type III Fc binding proteins. Comparison of different sources of protein G. J Immunol Methods 1989 0.75
131 Selective loss of expression of a tumor-associated antigen on a human leukemia cell line induced by treatment with monoclonal antibody and complement. J Natl Cancer Inst 1987 0.75
132 A simple preparative procedure to extract and purify protein G from group G streptococci. Prep Biochem 1991 0.75
133 1,10-Phenanthroline mediated hemolysis--evidence that 1,10-phenanthroline does not substitute specifically for C9. Mol Immunol 1979 0.75
134 Low antigen density tumor cells: an obstacle to effective autologous bone marrow purging? Cancer Invest 1987 0.75
135 A rapid alternative to the clonogenic assay for measuring antibody and complement-mediated killing of tumor cells. Clin Immunol Immunopathol 1985 0.75
136 The mitogenic activity of type III bacterial Ig binding proteins (protein G) for human peripheral blood lymphocytes is not related to their ability to react with human serum albumin or IgG. J Immunol 1991 0.75
137 Effect of lectins on the hemolytic activity of complement components. Immunochemistry 1978 0.75
138 Studies on the terminal stages of antibody-complement mediated killing of a tumor cell. III. Effect of membrane active agents. J Immunol 1976 0.75
139 Evidence for an anticomplementary factor associated with human bone marrow cells. J Natl Cancer Inst 1985 0.75
140 Isolation and partial characterization of a type IV bacterial immunoglobulin binding protein. Mol Immunol 1991 0.75
141 Detection of complement-dependent antibody to tumor cells in sera of strain-2 guinea pigs cured of their tumors by BCG Treatment. J Natl Cancer Inst 1976 0.75
142 Heterogeneity in the size and stability of transmembrane channels produced by whole complement. Clin Immunol Immunopathol 1981 0.75
143 Isolation of human plasma-inducible, growth phase- and temperature-regulated gene fusions in Streptococcus pyogenes using a Tn917-lacZ transposon. J Microbiol Methods 2001 0.75
144 The enn gene of group A streptococcal isolate A992 encodes an IgG3-binding protein. Dev Biol Stand 1995 0.75
145 Influence of dipeptides on the interaction of immunoglobulins with bacterial Fc receptors. Biochem Biophys Res Commun 1986 0.75